cad a22 4500 569303222 20200205045442.0 cr unu---uuuuu 190726e20190901xx s 000 0 eng 10.5167/uzh-171736 doi 10.1016/j.cllc.2019.05.013 doi (ZORA)oai:www.zora.uzh.ch:171736 610 ddc 31262689 pmid Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence [Elektronische Daten] [Max Lacour, Stefanie Hiltbrunner, Seok-Yun Lee, Alex Soltermann, Elisabeth Jane Rushing, Davide Soldini, Walter Weder, Alessandra Curioni-Fontecedro] closedAccess eu-repo BACKGROUND Despite recent studies, the effect of chemotherapy on programmed death-ligand 1 (PD-L1) expression remains controversial. In this study, we investigated whether PD-L1 expression is affected by platinum-based chemotherapy. Furthermore, we evaluated correlation of PD-L1 expression with oncogenic driver alterations. MATERIALS AND METHODS We retrospectively evaluated changes in PD-L1 expression by immunohistochemical (IHC) analysis in resected specimens and in biopsies at non-small cell lung cancer recurrence in patients receiving or not adjuvant chemotherapy after surgical resection. Four IHC score groups were defined: TC0< 1%, T≥ 1% and< 5%, TC2≥ 5% and< 50%, and TC3≥ 50%. RESULTS Thirty-six patients with adenocarcinoma were included. Twenty (56%) patients underwent adjuvant chemotherapy, and 16 (44%) patients did not receive adjuvant chemotherapy. PD-L1 expression was present in 10 (28%) of 36 initial tumor specimens. From patients receiving adjuvant chemotherapy, 7 (35%) of 20 tumor biopsies showed significant upregulation in PD-L1 expression at recurrence. In contrast, from patients with no adjuvant therapy, only 2 (12.5%) of 16 showed a change in PD-L1 expression. Six (17%) of 36 patients were PD-L1-negative in the primary tumor and turned positive at recurrence. KRAS mutation was present in 70% of patients expressing PD-L1. CONCLUSION PD-L1 expression in non-small cell lung cancer can change from primary to recurrence, implicating the need for re-biopsy at recurrence. Moreover, chemotherapy might increase expression of PD-L1, supporting a combinatorial therapy with chemotherapy and anti-PD(L)1 treatment. Clinic for Oncology and Hematology zora Institute of Pathology and Molecular Pathology zora Institute of Neuropathology zora Clinic for Thoracic Surgery zora Lacour Max joint author Hiltbrunner Stefanie joint author Lee Seok-Yun joint author Soltermann Alex joint author Rushing Elisabeth Jane joint author Soldini Davide joint author Weder Walter joint author Curioni-Fontecedro Alessandra joint author Clinical Lung Cancer 20(5):391-396 https://www.zora.uzh.ch/id/eprint/171736/1/Lacour_clinical_lung_cancer_2019.pdf text/html WWW-Backlink auf das Repository 1 Journal Article PeerReviewed zora ZORA 856 40 https://www.zora.uzh.ch/id/eprint/171736/1/Lacour_clinical_lung_cancer_2019.pdf text/html WWW-Backlink auf das Repository ZORA 700 1- Lacour Max joint author ZORA 700 1- Hiltbrunner Stefanie joint author ZORA 700 1- Lee Seok-Yun joint author ZORA 700 1- Soltermann Alex joint author ZORA 700 1- Rushing Elisabeth Jane joint author ZORA 700 1- Soldini Davide joint author ZORA 700 1- Weder Walter joint author ZORA 700 1- Curioni-Fontecedro Alessandra joint author ZORA 773 0- Clinical Lung Cancer 20(5):391-396 BK010053 XK010053 XK010000 ZORA ZORA ZORA Journal Article closedAccess